T1	Participants 65 112	737 patients with aggressive malignant lymphoma
T2	Participants 149 201	737 patients with aggressive malignant lymphoma (ML)
T3	Participants 656 755	Four hundred forty-two patients had intermediate-grade ML, 221 highgrade ML, and 74 unclassified ML
T4	Participants 757 941	Most of the patients had advanced disease: stage IIE (23%), III (13%), or IV (47%); 38% disseminated nodes; 38% two or more extranodal sites; and 41% a tumoral mass greater than 10 cm.
